Overview of clinical trials in CML - Not yet recruiting trials
Source: www.clinicaltrials.gov | Last update: July 25, 2025
On this page, you'll find a regularly updated list of not yet recruiting clinical trials focused on novel therapies - including study details, sponsors, estimated enrolment, locations and the number of study centres.
Download our searchable Excel file to filter by sponsor, compound, or trial phase
(Updated regularly; the current file is from June 2025)
For an overview of currently recruiting clinical trials in CML, click here.
Disclaimer
The information presented in this overview has been sourced from www.clinicaltrials.gov and reflects data available as of April 24, 2025. While the iCMLf strives to ensure accuracy, it is not responsible for any errors, updates, or changes that may have occurred since that date. This list is provided solely for informational purposes and is organized alphabetically by investigational compound. The iCMLf does not endorse or recommend any specific clinical trial, investigational drug, or sponsor mentioned. For the most current and comprehensive details - including eligibility criteria, study locations, and contact information - please consult the official listing on clinicaltrials.gov.
Asciminib
PEARL Study: PotEntial of Asciminib in the eaRly Treatment of CML (PEARL)
This Phase 2 randomized study aims to evaluate the efficacy and safety of asciminib alone or in combination with nilotinib in newly diagnosed chronic-phase CML patients, assessing deep molecular response, treatment continuation, and treatment-free remission over five years. More information
Clinicaltrials.gov Identifier: NCT06409936
Compound: Asciminib
Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto, p.fazi@gimema.it
Status: Not yet recruiting (estimated enrolment: 160 participants)
Location (Centres): Italy (exact site information not available)
A Study of Treatment-free Remission in Chronic Phase Chronic Myeloid Leukemia (AsterA)
This study aims to evaluate the efficacy of adding asciminib to tyrosine kinase inhibitors (TKIs) in achieving treatment-free remission (TFR) for chronic-phase CML patients who previously failed a TKI cessation study. More information
Clinicaltrials.gov Identifier: NCT06368414
Compound: Asciminib
Sponsor: Korean Society of Hematology, ksh.cml.wp@gmail.com
Status: Not yet recruiting (estimated enrolment: 100 participants)
Location (Centres): Rep. of Korea (exact site information not available)
HS-10382
Study of HS-10382 Combination in Patients With Chronic Myeloid Leukemia (CML)
This study aims to evaluate the efficacy of adding asciminib to tyrosine kinase inhibitors (TKIs) in achieving treatment-free remission (TFR) for chronic-phase CML patients who previously failed a TKI cessation study. More information
Clinicaltrials.gov Identifier: NCT06530810
Compound: HS-10382
Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd. dr_huyu@126.com
Status: Not yet recruiting (estimated enrolment: 100 participants)
Location (Centres): China (exact site information not available)
Olverembatinib (HQP1351)
TQB3911
Phase II Study Assessing the Efficacy and Toxicity of Olverembatinib Monotherapy in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase
Phase I clinical trial to explore the safety, tolerability, and initial efficacy of TQB3911 tablets in BCR::ABL fusion gene positive leukemia. More information
Clinicaltrials.gov Identifier: NCT06672263
Compound: TQB3911
Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. jiangqian@medmail.com.cn
Status: Not yet recruiting (estimated enrolment: 120 participants)
Location (Centres): China (5)